{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "NNE",
  "name": "Nano Nuclear Energy Inc.",
  "url": "https://orbyd.app/dossiers/NNE/",
  "json_url": "https://orbyd.app/dossiers/NNE.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78 (7/16), losing the prior $18.04 floor. Broken structure, $400M ATM armed against a ~$844M cap, first KRONOS revenue ~FY2030. Stand aside until a base forms above $22.",
  "invalidation_trigger": "A weekly close below $15.78 confirms the fresh 52-week low as a breakdown rather than a washout and opens undiscovered downside; secondarily, any 424B or 8-K disclosing ATM share sales into a bounce confirms dilution is capping every rally.",
  "catalyst_date": "2026-08-14",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-29",
  "invalidation_fired": true,
  "themes": [
    "nuclear-uranium"
  ],
  "tags": [
    "watchlist"
  ],
  "sources": [],
  "notes": [
    "2026-04-18: seed: Serenity/attention list",
    "2026-07-19: $18.04 prior 52-week floor LOST. New low $15.78 (2026-07-16), close ~$16.20, ~73% below the $60.87 high. Prior downside condition has fired.",
    "2026-07-14: Truist (Christopher Souther) initiated Hold, $22 PT — first published non-Buy, ~40% under the $46.25 five-analyst consensus. Consensus is the stale number.",
    "2026-05-26: STS acquisition ($13M, ~$7.1M TTM revenue, ~$1.3M NI) — no longer strictly pre-revenue, but ~$7M of logistics revenue against a ~$844M cap is not the story.",
    "Fiscal year ends September 30, so the August report is FQ3 FY26 for the quarter ended June 30; quarterly comparisons do not line up with calendar quarters.",
    "A $400M at-the-market program sits under a $900M shelf (S-3/A effective 2026-03-09). No 424B5 prospectus supplement appears in the record since 2026-03-13.",
    "Chairman and President Jiang Yu sells under a Rule 10b5-1 plan adopted September 2025, so individual disposals are pre-scheduled. Insider ownership is about 32.77%.",
    "Reactor revenue is years out: guidance targets a mid-to-late 2027 construction start and a 2030 full-scale KRONOS prototype at the University of Illinois Urbana-Champaign.",
    "The only revenue today is nuclear-fuel logistics from the May 2026 STS acquisition, roughly $7.1M revenue and $1.3M net income for the twelve months to 2025-12-31."
  ],
  "body_markdown": "## Current Thesis\n\nThe prior note set the burden at $17.50, the 2026-07-27 session high. That close sits above $18.04 — the level that held as the 52-week floor until it broke in mid-July and price ran to $14.71 on 2026-07-29. Two sessions have retraced the July breakdown, roughly 23% off that low.\n\nThey did it with no company input. The EDGAR record shows nothing filed after BlackRock's Schedule 13G/A of 2026-07-29 and the DEF 14A of 2026-07-28; the last 8-K is dated 2026-06-25, the last Form 4 2026-06-05, and the company news page lists nothing after the 2026-07-27 AFWERX release. Both advancing sessions had the group underneath them: Oklo +6.16% then +5.12% to $43.33, NuScale +7.01% then +5.33% to $9.49. NNE printed +10.50% and then +3.36% — ahead of both peers on day one, behind both on day two.\n\nSo the leg on offer is not a microreactor leg. That is Retail Squeeze mechanics, and the label on the NANO-specific narrative stays **DEAD**: four company releases landed between 2026-07-17 and 2026-07-27 — Virginia Nuclear Energy Consortium membership, the Fortil fuel-handling engineering collaboration, the AFWERX SBIR Phase I selection for KRONOS, and an Alliance Global Partners Buy/$46 initiation — and were followed two sessions later by a fresh 52-week low. Nine sessions of firm-specific news produced less than two sessions of sector beta.\n\n## Bull Case\n\n- 2026-08-04 — First close above $18.04 since that shelf broke in mid-July: $18.17 on a $18.65 high, versus the 2026-07-22 high of $18.35. The two-session sequence from the 2026-07-31 close of $15.91 is unbroken.\n- 2026-08-04 — Enterprise value $408.10M against a $975.70M capitalisation; cash and equivalents $570.20M, net cash $10.57 per share (58% of the $18.17 quote), total debt $2.60M.\n- 2026-08-05 — No 424B5 prospectus supplement has been filed since 2026-03-13, so the $400M at-the-market program under the S-3/A effective 2026-03-09 shows no draw in the filing record. No Form 4 since 2026-06-05, leaving two months without a scheduled insider disposal on record.\n- 2026-07-15 settlement — The base grew into the low, which is the supply that produced the +12.10% session of 2026-07-30 and the +10.50% of 2026-08-03.\n- 2026-06-25 — NRC formally began review activity on the KRONOS construction-permit application with the University of Illinois Urbana-Champaign, docketed 2026-05-20. The Part 50 pathway is live.\n- 2026-07-27 — AFWERX SBIR Phase I selection for KRONOS, the first named federal defence relationship attached to the reactor rather than the logistics subsidiary; AGP initiated Buy/$46 the same day, holding the seven-analyst published average at $42.17.\n\n## Bear Case\n\n- 2026-08-04 — 50-day moving average $21.54, 200-day $27.64. The $18.17 close sits 15.6% and 34.3% beneath them and 70% under the $60.87 high; 52-week change -46.54%.\n- 2026-08-04 — Consensus revenue $1.02M for FY2026 and $4.65M for FY2027 against a $975.70M capitalisation. Consensus EPS -$0.90 and -$1.13. Trailing operating cash flow -$23.26M.\n- 2026-08-04 — Neither advancing session carried a filing or a press release. The reclaim of $18.04 happened on 2,218,170 shares, barely above the 2,110,007 twenty-day average.\n- 2026-08-05 — No company announcement of the FQ3 FY26 call date. Last year the equivalent notice came on 2025-07-21 for a 2025-08-14 call, 24 days ahead; this year nothing has appeared with the provider-listed date roughly a week out. *Inference:* 2026-08-14 is both the 45-day filing deadline for a quarter ended 2026-06-30 and the date the FQ3 FY25 10-Q was filed.\n- 2026-08-04 — Shares outstanding 53.70M, up 41.30% year over year. The $400M ATM is undrawn on the record but armed against a sub-$1B capitalisation.\n- 2026-07-13 — Truist's Hold/$22 remains the only published non-Buy and the newest anchor. The $42.17 average rests on $45–$50 targets set between 2026-05-15 and 2026-07-27, all before the $14.71 low.\n\n## Setup & Price Structure\n\nThe July sequence: the $18.04 floor broke mid-July, a 52-week low printed at $15.78 on 2026-07-16, and a lower one at $14.71 on 2026-07-29. The recovery since is four sessions — 2026-07-30 +12.10% to $16.68, 2026-07-31 -4.62% to $15.91, 2026-08-03 +10.50% to $17.58, 2026-08-04 +3.36% to $18.17. Volumes across those four: 2,126,458 / 2,096,367 / 2,579,119 / 2,218,170. Only 2026-08-03 exceeded the 20-day average by a meaningful margin. A shelf reclaimed on ordinary volume is a weaker structure than the percentage move suggests.\n\nOverhead, in order: the 2026-07-22 high of $18.35, then the 50-day at $21.54, then Truist's $22. Beneath: the 2026-07-31 close of $15.91, then $14.71. Nothing between $18.17 and $21.54 has been tested since the breakdown, so there is no reference volume in that band.\n\nCrowding and positioning, as observables:\n\n- 31.24% of a 44.29M float per one provider, 39.52% of public float per another; 6.4 days to cover.\n- Beta 5.41 against a $975.70M capitalisation and a 44.29M float.\n- Retail-facing coverage clustered at the low: The Motley Fool published \"Nano Nuclear Energy Surges: What's Driving the Rally Today?\" on 2026-07-31 and \"This $17 Nuclear Stock Could Turn $5,000 Into a Fortune\" on 2026-08-01, the latter citing the $42 average target and a \"$10 trillion\" nuclear market framing attributed to Bank of America.\n- An earnings date roughly a week out that the company has not confirmed.\n- No insider Form 4 since 2026-06-05; Chairman and President Jiang Yu disposes under a Rule 10b5-1 plan adopted September 2025.\n- Issuance capacity: $400M ATM beneath a $900M shelf, no supplement filed since 2026-03-13.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-11 (est.)** — FINRA short interest for the 2026-07-31 settlement date. MarketBeat lists next publication at approximately 2026-08-15.\n- **~2026-08-14 (est.)** — FQ3 FY26 results and 10-Q for the quarter ended 2026-06-30. Provider-listed, not company-confirmed as of 2026-08-05.\n- **2026-08-14** — Q2 calendar-quarter 13F filing deadline.\n- Beyond the window: **2026-09-15**, virtual annual meeting — election of six directors and ratification of WithumSmith+Brown as auditor.\n\n## Elapsed catalysts\n\n- **2026-08-05** — NuScale Power Q2 2026 results after the close, call 5:00 p.m. ET. Zacks consensus revenue $1M, -87.6% year over year. *(passed 4d ago)*\n- **2026-08-07** — Oklo Q2 2026 results before the open, call 8:30 a.m. ET. Largest pure-play in the group at $7.54B on 2026-08-04. *(passed 2d ago)*\n\n## What Would Change Our Mind\n\nThe reclaim of $18.04 is one close old, it came on volume barely above the 20-day average, and both of its sessions were matched move-for-move by Oklo and NuScale. Three things would make it more than a beta echo: a company release that holds a bid into a second session — absent since 2026-07-17\n\nBreaking the leg: a weekly close below $15.91 retraces the entire 2026-08-03 and 2026-08-04 advance and returns price inside the July breakdown range with $14.71 the only reference beneath. Secondarily, the ~2026-08-14 print passing with no ATM disclosure, no schedule change and revenue tracking the $1.02M FY2026 consensus path spends the only dated firm-specific event before 2026-09-15 — while a 424B5 disclosing ATM sales into this bounce settles the dilution question the other way.\n\nMoving the narrative label off DEAD needs a weekly close above the $21.54 50-day average with a company release attached to it, not a group session.\n\n## Correlation Notes\n\n- Same-session comparison, 2026-08-03: NNE +10.50%, OKLO +6.16%, SMR +7.01%. 2026-08-04: NNE +3.36%, OKLO +5.12%, SMR +5.33%. On day two the 5.41 beta delivered less than the group it was tracking.\n- Two peer prints land ahead of NNE's: NuScale on 2026-08-05, Oklo on 2026-08-07. Both report before any NANO disclosure, so the group sets the tape the FQ3 print arrives into.\n- Policy capital has been flowing to gigawatt scale. New Jersey's $24B nuclear program announced 2026-07-14 was framed around Westinghouse AP1000 with Cameco and Brookfield named; no microreactor allocation appeared.\n- Enterprise value of $408.10M against $570.20M of reported cash means the market assigns the reactor program a negative value on the balance sheet as filed. Price discovery has migrated to the sector.\n- The only revenue line is STS nuclear-fuel logistics — roughly $7.1M revenue and $1.3M net income for the twelve months to 2025-12-31 — so there is no uranium-price or power-price linkage in the P&L, only in the headlines the group trades on.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-05T06:03:43+00:00",
  "last_synthesized": "2026-08-05",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}